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Background: Dermatomyositis and polymyositis are both types of idiopathic inflammatory myositis characterized
by inflammation and weakness of proximal skeletal muscles and skin rash.
Case: A 49-year-old Caucasian woman recently diagnosed with breast cancer classified as T1N2M0, stage IIIA,
presenting skin rash associated with heliotrope and Gottron’s papules. In addition, there was a progression to a
severe reduction in proximal muscle strength with severe dysphagia. The initial treatment was conducted, and the
patient recovered from all symptoms and followed adjuvant cancer management.
Treatment: At first, high dose of corticosteroid was administered as pulse therapy, and a radical mastectomy was
indicated due to the severe symptoms of the paraneoplastic syndrome. Then chemotherapy and radiotherapy were
applied, and oral corticoid associated with immunosupressive drug was administered for dermatomyositis control.
Discussion: The association between myositis and an increased risk of cancer has been demonstrated over the
years. This patient has a high probability of dermatomyositis diagnosis. The initial treatment with high dose of
glucocorticoids may result in an improvement of muscle lesions. Second-line treatment with azathioprine,
methotrexate, or cyclophosphamide may be required for aggressive disease. Removal of the cancer induces
improvement of paraneoplastic syndrome.
Conclusion: Dermatomyositis can be a clinical manifestation of a paraneoplastic syndrome in patients with breast
cancer. It is a rare diagnosis, and there is little evidence to guide treatment until now. It is possible to control the
evolution of dermatomyositis with high doses of glucocorticoids in almost all cases; however, in severe cases of
paraneoplastic syndrome, cancer treatment should start immediately.
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Dermatomyositis (DM) and polymyositis (PM) are both
types of idiopathic inflammatory myopathies (IIM) char-
acterized by inflammation and weakness of proximal
skeletal muscles. DM disease is presented with specific
cutaneous signs. Myositis can affect various organs with
extra muscular manifestations: lungs, heart, joints, and
intestine [1-3]. Muscle inflammation and weakness are
the key features of this myopathy [4].
The reported incidence for DM varies from 0.5 to 0.89
per 100,000/year [3], affecting mostly middle-aged
women in a 2:1 ratio with men in the same age group.* Correspondence: lpndias@hotmail.com
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unless otherwise stated.In general, it is described as idiopathic, but malignancies
associated with myopathies have been extensively re-
ported in the medical literature since 1916 and then
confirmed by subsequent meta-analyses [5,6].
The type of malignancy generally reflects those found
in age and sex matched populations. Lung and colorectal
cancers were the most common cancers in men from
Western country cohorts; however, among women, 20%
is related to breast neoplasia [5,6].
The authors of this study reported a case of breast
cancer in an unusual presentation in order to arouse the
attention of professionals, guide diagnosis and establish
appropriate management in severe cases.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 2 Gottron’s papules.
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A 49-year-old Caucasian woman with a tumor in the left
axilla came to evaluation at the Pérola Byington Hospital
(PBH) in São Paulo, Brazil. The ultrasound revealed an
irregular breast nodule measuring 1.8 cm, suspected of
malignancy, in the lower medial quadrant of the left
breast, and an axillary lymph node of 3.5 cm, clinically
matted. Both underwent core needle biopsy, and the
diagnosis was invasive carcinoma of no special type,
histological, and nuclear grade III and II, respectively.
The tumor was positive for hormone receptors (estrogen
and progesterone), Her2/neu +3/+3 and Ki-67 40%. Ac-
cording to the first evaluation, the cancer stage on TNM
classification was IIIA (cT1cN2cM0) [7]. The screening
for metastasis was negative.
On the following month, the patient developed a char-
acteristic group of signs and symptoms. First appeared
was erythema on the face, trunk, and extensor areas of
the limbs. Also, heliotrope and Gottron’s papules were
identified (Figures 1 and 2). The heliotrope eruption
consists of a violaceous or dusky erythema with edema
in a periorbital distribution. When it occurs bilaterally, it
may be a subtle skin finding as it often only involves the
upper lid. Gottron’s papules are found over bony promi-
nences, particularly the knuckles. They consist of slightly
elevated, violaceous to dusky red papules or plaques that
may develop a poikilodermatous appearance and may
become atrophic. These lesions can be confused with
those of systemic lupus erythematosus [8].
One week after, a significant weakness started, followed
by progressive reduction on proximal muscle strength in a
symmetric distribution associated with progressive as-
cendant edema. On the fourth week, severe edema and
dysphagia were identified. After 1 month, the patient was
restricted to bed, unable to perform any daily activity, and
she was brought to be evaluated in PBH (Figure 3). During
those 4 weeks, the patient was evaluated by the primaryFigure 1 Heliotrope.care physicians and just symptomatic medication was
offered.
The patient was admitted to the ward, and the labora-
tory tests showed creatine kinase (CPK) of 34,875 U/L,
aspartate aminotransferase of 786 U/L, alanine amino-
transferase of 352 U/L and lactate dehydrogenase of
4,103 U/L. The high clinical suspicion of DM and the se-
verity of the condition guided the medical team to initi-
ate the treatment immediately.
It is well known that CPK is a toxic substance for the
kidney, and in order to prevent kidney acute lesions, it
was offered an intravenous great amount of physiologic
solution 0.9%, aiming a diuresis of 300 ml/h or more
and a glicophysiological solution 5% with sodium bicar-
bonate, to reduce urine acidosis, associated or not with
mannitol [9]. High dose of corticosteroid was adminis-
tered as pulse therapy, using methylprednisolone 1 g/
day, for three consecutive days [8]. After the first dose of
pulse therapy, the patient related that the progression ofFigure 3 The patient, on the second day on the ward, restricted
to bed, unable to do any activity.
Figure 5 Skin rash 2 weeks after surgery. There is an almost
complete remission of the lesion.
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line, a cancer stage IIIA should be treated with preopera-
tive chemotherapy [10], but considering the clinical
suspicious of DM as a paraneoplastic syndrome, some pa-
pers describe faster recovery of the dermatomyositis
symptoms if the resection of the cancer is realized prior to
the chemotherapy [11-14]. A medical meeting decided for
radical mastectomy with axillary dissection, and the pro-
cedure was performed on the following week.
The histopathological examination revealed primary
tumor of 2.0 cm, with metastasis in 8 of 16 axillary
lymph nodes. Also, the histopathological cutaneous bi-
opsy analysis was performed, and the skin biopsy speci-
men revealed a superficial perivascular lymphocytic
infiltrate with vacuolar degeneration and necrotic kerati-
nocytes along the basement membrane, epidermal
hyperplasia with focal areas of atrophy, and compact
orthokeratosis (Figure 4).
There were no postoperative complications, and after
2 weeks, full remission of the edema and gradual recov-
ery of muscle strength and swallowing capacity were evi-
dent (Figure 5). In the third week, the patient was
already able to walk with assistance and was discharged
to follow up with the team of clinical oncology.
On the follow-up, the patient was submitted to adjuvant
treatment: first, chemotherapy with 6 cycles of cyclopho-
phamide (500 mg/m2), doxorubicin (60 mg/m2), and pac-
litaxel (175 mg/m2) and a rest period of 21 days, followed
by trastuzumab with initial dose of 8 mg/kg and mainten-
ance dose of 6 mg/kg, for 18 cycles, with 21 days of rest
period.
Second, after concluding the first 6 cycles, the patient
was submitted to 25 radiotherapy sessions on the chest
wall and supraclavicular fossa, with a total of 50 Gy
(2 Gy/day).Figure 4 Skin rash 1 week after surgery. Improvement of the
lesion after the resection of the tumor mass is remarkable.Third, the patient was evaluated and verified that she
was on menopause, and an aromatase inhibitor was initi-
ated. The first choice was anastrozole, on the dose of
1 mg/day, during 5 years.
On the other hand, the treatment of the paraneoplastic
syndrome was maintained with oral corticoid, initially
with 1 mg/kg of prednisone. After 1 year of follow-up,
we introduced azathioprine, 2 mg/kg oral daily, and the
oral corticoid was reduced to 10 mg. On two occasions,
the medical team suspended the corticoid, and after a
few days, the skin rash appeared again. So, after recheck-
ing the literature, our group decided to keep the corti-
coid on the lowest dose possible, and 10 mg is the
minimum that the patient accepts with no symptoms
[8,15,16].
Due to the chronic use of oral corticoid associated to
anastrozole, the medical team introduced oral calcium
carbonate plus vitamin D [17].
The last screening for metastasis, after 18 months of
follow-up, was negative and the DM was controlled.Discussion
The association between IIM and cancer has been exten-
sively studied in adults. Many epidemiological studies
demonstrated this association, which appears stronger for
DM than for PM. The first case suggesting an association
between cancer and DM was reported in 1916. At present,
the reported incidence of cancer association with DM var-
ies widely, from less than 7% to over 30% [18-21]. One
paper has reported that malignancy may precede myop-
athy by 2 years [22], while another have described neopla-
sias in DM even after 5 years of disease [23]. Thus,
ovarian cancer or breast cancer in females and lung cancer
in males are the main malignancies associated with DM
[3,18,19].
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ter’s criteria, and the patient should have a typical rash
and at least three of following manifestations: symmetric
proximal muscle weakness, muscle biopsy evidence of
myositis, increase in serum skeletal muscle enzymes, and
characteristic electromyographic pattern. The patient in
this case study had the typical skin rash (Figure 6) and
two other manifestations related to DM, with high clinical
suspicious of the diagnosis [24].
Other symptoms can occur and may include pitting
edema, dysphagia secondary to bulbar muscle weakness,
and nasal regurgitation of liquids or aspiration pneumo-
nia and dyspnea [11].
Patients with DM have an increased incidence of hu-
man leukocyte antigen (HLA)-B8 and HLA-DR3. There
is a significant association between patients with myo-
sitis and antibodies to histidyltransfer RNA synthetase
(Jo-1antigen), which has been linked to the HLA-DR3
antigen. Anti-Jo-1antibody positive patients may have an
increased risk for the development of interstitial pul-
monary disease [8]. In addition, the possible autoanti-
bodies related were not assessed in this study.
The management of DM/PM is based on diagnostic
accuracy, assessment of disease activity prevention, pa-
tient education, and psychosomatic support [8]. Despite
the lack of evidence from controlled trials to guide treat-
ment, corticosteroids remain the agents of choice for in-
flammatory myopathy [15]. Patients with DM treated
with high-dose prednisone generally have a good initial
response, with rates of initial remission varying from
27% to 87%. Not all types of myositis, however, respond
favorably to corticosteroids, and some authors initially add
a first-line immunosuppressive agent in combination with
high-dose corticosteroids in severe cases of myositis
[15,16]. Indeed, immunosuppressive agents are both steroid
sparing and effective, serving to mitigate corticosteroid-
related side effects and at the same time treating theFigure 6 Typical skin rash, with atrophic areas on the trunk.aforementioned serious extra muscular manifestations, al-
though there is a need to weigh the increased risks of im-
munosuppression [15].
Methotrexate may be successfully used as a corticoster-
oid sparing agent in the treatment of DM. A therapeutic
effect may not be seen for 4 to 8 weeks. The recom-
mended oral dose is 5 to 20 mg/week. Patients must be
monitored for hepatotoxicity, renal insufficiency, and pul-
monary fibrosis. Azathioprine is an alternative agent ef-
fective at doses of 2 to 3 mg/kg/day in divided doses, with
a maintenance dose of 0.5 mg/kg/day. Hematologic moni-
toring is essential to detect leukopenia and anemia [8].
Treatment with high dose of glucocorticoids may re-
sult in an improvement of CPK levels within the first
couple of weeks. There is often a delay before muscle
strength recovers, at that time, standard breast cancer
therapies are recommended. In patients with breast can-
cer and DM, the role of neoadjuvant chemo/hormonal
therapy is debatable, and there is no solid data available
in this setting, and the response can be slower than with
surgical treatment [11,12,25].
Age, severity of muscle disease, and systemic involve-
ment all affect the prognosis of patients with DM and
PM. Studies have shown a poor outcome in patients
with pulmonary fibrosis and dysphagia. Rapid response
to corticosteroid therapy has been associated with a fa-
vorable prognosis [8].Conclusion
DM can be a clinical manifestation of a paraneoplastic
syndrome in patients with breast cancer. It is a rare diag-
nosis, and there is little evidence to guide treatment until
now. It is possible to control the evolution of DM with
high doses of glucocorticoids associated with immunosup-
pressive agents and treat cancer with surgery as soon as
possible [13,14]. Removal of the cancer induces improve-
ment of paraneoplastic syndrome [12].Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor in Chief of this journal.
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